Oxford Nanopore Technologies Stock
Oxford Nanopore Technologies plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Francis Albert Luc Van Parys
- Employees
- 1,314
- Market cap
- £2 B
- IPO
- 30/09/2021
Oxford Nanopore Technologies plc is a United Kingdom-based enterprise within the healthcare sector that specializes in developing and commercializing innovative systems for analyzing diverse molecular structures through nanopore-based sensing. Founded in 2005, the company was originally known as Oxford NanoLabs…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Oxford Nanopore Technologies stock: price history
1D
-4.6%
1W
-6.3%
1M
+24.0%
6M
+58.0%
YTD
+55.8%
1Y
+40.8%
2Y
+39.6%
5Y
-66.4%
10Y
–
Next earnings date
Next earnings date
09/03/2027 (in 143 days)
Volatility around earnings
~49% stronger price swings than usual
Ask the agents about Oxford Nanopore Technologies
Oxford Nanopore Technologies stock metrics
P/E
-12.54
P/B
4.57
EV/EBITDA
-16.32
RETURN ON EQUITY
-11.3%
NET MARGIN
-41.1%
DEBT/EQUITY
0.1
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
28.1%
FLOAT SHARES
274,769,218
AVG. DAILY VOLUME (30D)
3,328,999
Comparable stocks
Frequently asked questions about Oxford Nanopore Technologies stock
What does Oxford Nanopore Technologies do?
Oxford Nanopore Technologies plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Francis Albert Luc Van Parys, the company employs around 1,314 people.
The IPO was on 30/09/2021; the stock trades on LSE under the ticker ONT.L.
When does Oxford Nanopore Technologies report next?
The next earnings date is 09/03/2027.
Around past earnings, price swings were roughly 49% stronger than usual.
Does Oxford Nanopore Technologies pay a dividend?
No, Oxford Nanopore Technologies currently does not pay a dividend.
Which stocks are comparable to Oxford Nanopore Technologies?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Oxford Nanopore Technologies stock analyzed?
Clicking "Analyze stock" lets five strategies assess Oxford Nanopore Technologies against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.